Researcher's surprising finding could lead to glanders vaccine

October 19, 2012
Results from this western blot analysis suggest that B. thailandensis ATPK01 (lane 5) contains immunogens that would generate protective immunity against B. mallei infection.

(Medical Xpress)—Apichai Tuanyok dedicated several years to working on a bacterial pathogen in Canada, but his breakthrough occurred in Flagstaff with an unexpected finding on a routine lab report.

Although the Tuanyok is investigating at Northern Arizona University is closely related to, but not the same, as the one he had researched in Canada, the results felt like a payoff for all the effort.

"I emailed many people that day," Tuanyok said, recalling his excitement at the lab report filed by his graduate student. What Tuanyok wrote in the email was that he possibly had found a vaccine target for glanders, a severe infectious disease that is usually limited to horses and donkeys but has potential as a biowarfare agent.  

Follow-up tests at NAU's Center for and Genomics (MGGen), where Tuanyok is an assistant research professor of biological sciences, have convinced Tuanyok that "we have the right target, but we have to identify further what bacterial species would be a good candidate" for an effective vaccine.

What Tuanyok found was that a common known as ATPK 1 plays a role in generating against glanders infection, with a 70 percent survival rate among infected .

Glanders, caused by the bacterium Burkholderia mallei, occurs in several countries in the Middle East, Mediterranean and South America. Human infection is uncommon but when it occurs, the bacterium is highly antibiotic resistant. No vaccine currently exists.

The Department of Defense has taken an interest because the bacterium, in aerosolized form, could be used as a bioweapon. During the , it is believed that Germany used methods to spread glanders intentionally, infecting Russian horses and mules used by the military. It was also used by the Japanese in .

Tuanyok is working on a manuscript with Paul Keim, NAU Regents' professor and director of MGGen, to describe the research and hopefully generate more funding.

It was Keim, in fact, who brought Tuanyok to the MGGen lab based on his work with melioidosis, a tropical disease that claims thousands of lives each year in Tuanyok's native Thailand. The bacterium behind that disease, Burkholderia pseudomallei, was still Tuanyok's focus when he first arrived at NAU in 2006. He may yet return to it.

"The vaccine we're working on may not be used for another disease," Tuanyok said, "but I have another idea for melioidosis and I may be able to do some work in parallel."

Explore further: Anthrax capsule vaccine protects monkeys from lethal infection

Related Stories

Recommended for you

Molecular Zika study finds possible target for tests, drugs

April 19, 2016

The molecular structure of the Zika virus as seen on x-ray crystallography revealed electrostatic differences in a key protein compared with other flaviviruses that might explain how it infects human cells, according to a ...

Zika virus may now be tied to another brain disease

April 10, 2016

The Zika virus may be associated with an autoimmune disorder that attacks the brain's myelin similar to multiple sclerosis, according to a small study that is being released today and will be presented at the American Academy ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.